Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma

N/ANot Yet RecruitingNCT06331260

Zhejiang University600 enrolled

Overview

As key biomarkers in HCC, AFP and PIVKA-II reflects biological features of tumor and has been widely applied for clinical diagnosis. Previous studies reported preoperative AFP and PIVKA-II are related to HCC recipient long-term survival after liver transplantation. However, there is no prospective study supporting these conclusions. This study aims to prospective collect liver transplantation cases from multiple transplant centers and further evaluate the prognostic role of preoperative AFP and PIVKA-II in liver transplantation for HCC.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Liver Transplantation Hepatocellular Carcinoma Alpha-Fetoprotein Protein Induced by Vitamin K Absence or Antagonist-II

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of HCC based on CT or MRI imaging or needle biopsy confirming a histologic diagnosis of HCC. 2. Patients undergoing deceased donor liver transplantation for the first time. Exclusion Criteria: (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up, (5) taking warfarin at the time of LT biomarker measurements

Outcomes

Primary Outcomes

Recurrence free survival rate

Time frame: 2024.4.1-2028.4.1

Overall survival rate

Time frame: 2024.4.1-2028.4.1

Tumor recurrence rate

Time frame: 2024.4.1-2028.4.1